Treatment options for Crohn’s disease expand after Rinvoq approval
Pharmaceutical Technology
MAY 19, 2023
The FDA nod means Rinvoq is now approved for seven indications in gastroenterology, rheumatology and dermatology. In a January presentation, the company shared that approvals in additional indications would allow Rinvoq and Skyrizi, a monoclonal antibody, to gain peak share in the different markets, including inflammatory bowel disease.
Let's personalize your content